Hepatocellular cancer in HIV-infected individuals: Tomorrow's problem?

Expert Review of Anticancer Therapy

Volumn 6, Issue 11, 2006, Pages 1553-1558

  Powles, Thomas ^a   Macdonald, Douglas ^b   Nelson, Mark ^b   Stebbing, Justin ^b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Cirrhosis; Hepatitis; Hepatocellular cancer; HIV

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; HEPATITIS B ANTIBODY; INTERFERON; PROTEIN INHIBITOR; RIBAVIRIN; TACROLIMUS;

CANCER INCIDENCE; CANCER THERAPY; CARCINOGENESIS; DISEASE ASSOCIATION; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; OUTCOME ASSESSMENT; PATIENT CARE; PREDICTION; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CARCINOMA, HEPATOCELLULAR; FORECASTING; HEPATITIS B; HIV INFECTIONS; HUMANS; LIVER NEOPLASMS;

EID: 33845363796     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.11.1553     Document Type: Review

References (54)

1. Grulich AE. Update: cancer risk in persons with HIV/AIDS in the era of combination antiretroviral therapy. AIDS Read. 10(6), 341-346 (2000).
2. Gingues S, Gill MJ. The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta. HIV Med. 7(6), 369-377 (2006).
3. Frisch M, Biggar RJ, Engels EA, Goedert JJ; AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA 285(13), 1736-1745 (2001).
4. Mbulaiteye SM, Parkin DM, Rabkin CS. Epidemiology of AIDS-related malignancies an international perspective. Hematol. Oncol. Clin. North Am. 17(3), 673-696 (2003).
5. Pantanowitz L, Schlecht HP, Dezube BJ. Growing problem of non-AIDS-defining malignancies in HIV. Curr. Opin. Oncol. 18(5), 469-478 (2006).
6. Anthony PP. Hepatocellular carcinoma: an overview. Histopathology 39, 109-118 (2001).
7. Chen CJ, Yang HI, Su J. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295, 65-73 (2006).
8. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am. J. Gastroenterol. 101(8), 1797-1803 (2006).
9. Toyoda H. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C. J. Viral Hepat. 7(6), 414-419 (2000).
10. Szabo E, Paska C, Kaposi Novak P, Schaff Z, Kiss A. Similarities and differences in hepatitis B and C virus induced hepatocarcinogenesis. Pathol. Oncol. Res. 10(1), 5-11 (2004).
11. Andrisani OM, Baranabas S. The transcriptional function of hepatitis B virus protein x and its role in hepatocarcinogenesis. Int. J. Oncol. 15, 373-379 (1999).
12. Okuda M, Li K, Beard MR et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122(2), 366-375 (2002).
13. Chemin I, Trepo C. Clinical impact of occult HBV infections. J. Clin. Virol. 34 (Suppl. 1), S15-S21 (2005).
14. Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J. Clin. Virol. 35(1), 14-20 (2006).
15. Shiota G, Oyama K, Udagawa A et al. Occult hepatitis B virus infection in HBs antigen-negative hepatocellular carcinoma in a Japanese population: involvement of HBx and p53. J. Med. Virol. 62(2), 151-158 (2000).
16. Higashi Y, Tada S, Miyase S et al. Correlation of clinical characteristics with detection of hepatitis B virus X gene in liver tissue in HBsAg-negative, and HCV-negative hepatocellular carcinoma patients. Liver 22(5), 374-379 (2002).
17. Pollicino T, Squadrito G, Cerenzia G et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 126(1), 102-110 (2004).
18. Tanaka Y, Kurbanov F, Mano S et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology 130(3), 703-714 (2006).
19. Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284(4), 450-456 (2000).
20. Smukler AJ, Ratner L. Hepatitis viruses and hepatocellular carcinoma in HIV-infected patients. Curr. Opin. Oncol. 14(5), 538-542 (2002).
21. Bruno R, Gazzaruso C, Sacchi P et al. High prevalence of metabolic syndrome among HIV-infected patients: link with the cardiovascular risk. J. Acquir. Immune Defic. Syndr. 31(3), 363-365 (2002).
22. Thio CL, Seaberg EC, Skolasky R Jr et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360, 1921-1926 (2002).
23. Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 36(3), 869-875 (2004).
24. Hyun CB, Coyle WJ. Hepatocellular carcinoma in a patient with human immunodeficiency virus and hepatitis B virus coinfection: an emerging problem? South Med. J. 97(4), 401-406 (2004).
25. Puoti M, Bruno R, Soriano V et al. HIV HCC Cooperative Italian-Spanish Group. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 18(17), 2285-2293 (2004).
26. Salmon-Ceron D, Lewden C, Morlat P et al. The Mortality (2000) study group. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J. Hepatol. 42(6), 799-805 (2005).
27. Altavilla G, Caputo A, Lanfredi M, Piola C, Barbanti-Brodano G. Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene. Am. J. Pathol. 157(4), 1081-1089 (2000).
28. Hyun CB, Coyle WJ. Related hepatocellular carcinoma in a patient with human immunodeficiency virus and hepatitis B virus coinfection: an emerging problem? South Med. J. 97 (4), 401-406 (2004).
29. Powles T, Nelson M, Bower M. HIV-related lung cancer - a growing concern? Int. J. STD AIDS 14(10), 647-651 (2003).
30. Prakash O, Mason A, Luftig RB, Bautista AP. Hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1) infections in alcoholics. Front. Biosci. 7, E286-E300 (2002).
31. Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J. Acquir. Immune Defic. Syndr. 32 (5), 527-533 (2003).
32. Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El-Serag HB. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am. J. Gastroenterol. 100(1), 56-63 (2005).
33. Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch. Intern. Med. 164(21), 2349-2354 (2004).
34. Clifford GM, Polesel J, Rickenbach M et al. Swiss HIV Cohort. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J. Natl Cancer Inst. 97(6), 425-432 (2005).
35. Herida M, Mary-Krause M, Kaphan R et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J. Clin. Oncol. 21(18), 3447-3453 (2003).
36. Lewden C, Salmon D, Morlat P et al. Mortality (2000) study group. Causes of death among human immunodeficiency virus (HIV-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int. J. Epidemiol. 34(1), 121-130 (2005).
37. Rosenthal E, Poiree M, Pradier C et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France. AIDS 17(12), 1803-1809 (2003).
38. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362(9399), 1907-1917 (2003).
39. Bruix J, Sherman M, Llovet JM et al. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 35(3), 421-430 (2001).
40. Powles T, Bower M, Daugaard G et al. Multicenter study of human immunodeficiency virus-related germ cell tumors. J. Clin. Oncol. 21 (10), 1922-1927 (2003).
41. Ettorre GM, Vennarecci G, Boschetto A et al. Resection and transplantation: evaluation of surgical perspectives in HIV positive patients affected by end-stage liver disease. J. Exp. Clin. Cancer Res. 22(4 Suppl.), 167-169 (2003).
42. Ragni MV, Belle SH, Im K et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J. Infect. Dis. 188(10), 1412-1420 (2003).
43. Klassen MK, Lewin-Smith M, Frankel SS, Nelson AM. Pathology of human immunodeficiency virus infection: noninfectious conditions. Ann. Diagn. Pathol. 1(1), 57-64 (1997).
44. Neff GW, Bonham A, Tzakis AG et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl. 9(3), 239-247 (2003).
45. Roland ME, Stock PG. Liver transplantation in HIV-infected recipients. Semin. Liver Dis. 26(3), 273-284 (2006).
46. Di Benedetto F, De Ruvo N, Berretta M et al. Don't deny liver transplantation to HIV patients with hepatocellular carcinoma in the highly active antiretroviral therapy era. J. Clin. Oncol. 24(14), E26-E27 (2006).
47. Hughes CA, Shafran SD. Treatment of hepatitis C in HIV-coinfected patients. Ann. Pharmacother. 40(3), 479-489 (2006).
48. Chung RT, Hepatitis C and B viruses: the new opportunists in HIV infection. Top. HIV Med. 14(2), 78-83 (2006).
49. Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J. Hepatol. 27(1), 18-24 (1997).
50. Dimitrakopoulos A, Takou A, Haida A, Molangeli S, Gialeraki A, Kordossis T. The prevalence of hepatitis B and C in HIV-positive Greek patients: relationship to survival of deceased AIDS patients. J. Infect. 40(2), 127-131 (2000).
51. Sungkanuparph S, Vibhagool A, Manosuthi W et al. Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study. J. Med. Assoc. Thai. 87(11), 1349-1354 (2004).
52. Gonzalez-Garcia JJ, Mahillo B, Hernandez S et al. Prevalences of hepatitis virus coinfection and indications for chronic hepatitis C virus treatment and liver transplantation in Spanish HIV-infected patients, The GESIDA 29/02 and FIPSE 12185/01 Multicenter Study. Enferm. Infec. Microbiol. Clin. 23(6), 340-348 (2005).
53. Lincoln D, Petoumenos K, Dore GJ; Australian HIV Observational Database. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med. 4(3), 241-249 (2003).
54. Rouet F, Chaix ML, Inwoley A et al. ANRS (1236) DITRAME-B&C Study Group. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Cote d'Ivoire: the ANRS (1236) study. J. Med. Virol. 74(1), 34-40 (2004).